{"id":"placebo-for-toripalimab","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4297843","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo serves as a control comparator in clinical trials and contains no active pharmaceutical ingredient. It is used to establish the baseline efficacy and safety profile of the investigational drug toripalimab (a PD-1 inhibitor) by comparison against a non-therapeutic control arm.","oneSentence":"Placebo is an inert substance with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:27.410Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 trials of toripalimab for cancer indications"}]},"trialDetails":[{"nctId":"NCT07174947","phase":"PHASE2","title":"SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-01","conditions":"Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders","enrollment":240},{"nctId":"NCT04523493","phase":"PHASE3","title":"Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2020-06-29","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":530},{"nctId":"NCT07191405","phase":"NA","title":"Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-09-18","conditions":"Immunotherapy, Chemotherapy","enrollment":156},{"nctId":"NCT03581786","phase":"PHASE3","title":"The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2018-10-18","conditions":"Recurrent or Metastatic NPC","enrollment":289},{"nctId":"NCT04085276","phase":"PHASE3","title":"Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2018-12-21","conditions":"Triple-Negative Breast Cancer","enrollment":531},{"nctId":"NCT05342194","phase":"PHASE3","title":"Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-06-19","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":480},{"nctId":"NCT06712888","phase":"PHASE3","title":"Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-02-17","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":466},{"nctId":"NCT05180734","phase":"PHASE3","title":"PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2022-02-10","conditions":"Gastric or Esophagogastric Junction Adenocarcinoma","enrollment":878},{"nctId":"NCT05869227","phase":"PHASE3","title":"Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"XIANG YANQUN","startDate":"2023-04-28","conditions":"Nasopharyngeal Carcinoma, Maintenance Therapy","enrollment":166},{"nctId":"NCT04158440","phase":"PHASE3","title":"Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2020-04-07","conditions":"Stage II-III Non-small Cell Lung Cancer","enrollment":501},{"nctId":"NCT06095583","phase":"PHASE3","title":"Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-11-15","conditions":"Limited-stage Small Cell Lung Cancer (LS-SCLC)","enrollment":756},{"nctId":"NCT03925090","phase":"PHASE2","title":"Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-12-08","conditions":"Nasopharyngeal Carcinoma","enrollment":150},{"nctId":"NCT04462965","phase":"PHASE2","title":"Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2020-05-30","conditions":"Mucosal Melanoma","enrollment":294},{"nctId":"NCT04772287","phase":"PHASE3","title":"Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2021-03-31","conditions":"Non Small Cell Lung Cancer","enrollment":341},{"nctId":"NCT04568304","phase":"PHASE3","title":"A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma","status":"UNKNOWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2020-11-30","conditions":"Locally Advanced or Metastatic Urothelial Carcinoma","enrollment":364}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for toripalimab","genericName":"Placebo for toripalimab","companyName":"Shanghai Junshi Bioscience Co., Ltd.","companyId":"shanghai-junshi-bioscience-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo is an inert substance with no active pharmacological mechanism. Used for Control arm in phase 3 trials of toripalimab for cancer indications.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}